Zacks: Brokerages Anticipate Cardlytics Inc (NASDAQ:CDLX) Will Announce Earnings of -$0.52 Per Share

Wall Street brokerages expect Cardlytics Inc (NASDAQ:CDLX) to announce ($0.52) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Cardlytics’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.41). Cardlytics posted earnings of ($0.12) per share during the same quarter last year, which indicates a negative year over year growth rate of 333.3%. The business is scheduled to announce its next quarterly earnings results on Thursday, August 13th.

On average, analysts expect that Cardlytics will report full-year earnings of ($1.12) per share for the current fiscal year, with EPS estimates ranging from ($1.39) to ($0.84). For the next year, analysts anticipate that the firm will post earnings of ($0.09) per share, with EPS estimates ranging from ($0.61) to $0.20. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Cardlytics.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.09. The company had revenue of $45.51 million during the quarter, compared to analysts’ expectations of $42.97 million. Cardlytics had a negative return on equity of 19.42% and a negative net margin of 11.08%. The business’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.23) earnings per share.

A number of research firms have recently issued reports on CDLX. Zacks Investment Research cut shares of Cardlytics from a “hold” rating to a “sell” rating in a research report on Monday, June 15th. TheStreet cut Cardlytics from a “c-” rating to a “d” rating in a research note on Wednesday, March 18th. BidaskClub downgraded shares of Cardlytics from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 13th. SunTrust Banks increased their target price on shares of Cardlytics from $50.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Finally, Bank of America cut shares of Cardlytics from a “buy” rating to an “underperform” rating and set a $26.00 price target on the stock. in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company. Cardlytics has a consensus rating of “Hold” and a consensus price target of $54.86.

In related news, COO Lynne Marie Laube sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $41.58, for a total value of $2,079,000.00. Following the transaction, the chief operating officer now owns 324,302 shares in the company, valued at $13,484,477.16. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Scott D. Grimes sold 37,500 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $43.30, for a total value of $1,623,750.00. Following the transaction, the chief executive officer now directly owns 370,055 shares of the company’s stock, valued at $16,023,381.50. The disclosure for this sale can be found here. Insiders sold a total of 215,759 shares of company stock worth $11,065,783 over the last three months. 6.50% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of the company. American International Group Inc. raised its stake in Cardlytics by 3.2% in the 4th quarter. American International Group Inc. now owns 8,964 shares of the company’s stock valued at $563,000 after acquiring an additional 275 shares during the period. Bank of Montreal Can increased its stake in shares of Cardlytics by 3.6% in the fourth quarter. Bank of Montreal Can now owns 17,314 shares of the company’s stock worth $1,088,000 after purchasing an additional 598 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Cardlytics by 4.3% in the first quarter. Alliancebernstein L.P. now owns 17,100 shares of the company’s stock valued at $598,000 after purchasing an additional 700 shares during the period. Royal Bank of Canada raised its position in shares of Cardlytics by 30.2% in the first quarter. Royal Bank of Canada now owns 4,737 shares of the company’s stock valued at $166,000 after purchasing an additional 1,099 shares during the period. Finally, Great West Life Assurance Co. Can purchased a new stake in shares of Cardlytics during the 4th quarter valued at approximately $83,000. Institutional investors own 83.51% of the company’s stock.

Shares of Cardlytics stock traded up $0.66 during trading on Friday, reaching $67.50. 436,692 shares of the company traded hands, compared to its average volume of 853,106. The firm has a market capitalization of $1.80 billion, a PE ratio of -66.83 and a beta of 2.54. Cardlytics has a 1-year low of $26.07 and a 1-year high of $107.50. The company has a 50 day moving average price of $70.24 and a 200-day moving average price of $64.34.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: What are the benefits of momentum investing?

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.